Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 122

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 122
---
 business will be integrated into our Cardiology division.In addition, in the third quarter of 2025, we completed the acquisition of another business for which the transaction price consisted of an upfront cash payment of $73 million, net of cash acquired. Purchase Price Allocation We accounted for these transactions as business combinations in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805). The preliminary purchase prices were comprised of the amounts presented below: (in millions)Bolt MedicalSoniVieOtherPayment for acquisition, net of cash acquired$475 $362 $593 Fair value of contingent consideration100 98 38 Fair value of prior interest207 55 — $782 $516 $631 We recorded the assets acquired and liabilities assumed at their respective fair values as of the closing date of the transaction. The preliminary purchase price allocations were comprised of the components presented below, which represent the preliminary determination of the fair value of assets acquired and liabilities assumed, with the excess of the purchase price over the fair value of net identifiable assets acquired recorded to goodwill. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with FASB ASC Topic 805. 

10

Table of Contents

(in millions)Bolt MedicalSoniVieOtherGoodwill$304 $248 $408 Amortizable intangible assets142 — 216 Indefinite-lived intangible assets376 344 — Other assets acquired28 12 91 Net deferred tax assets— — 11 Liabilities assumed(22)(23)(55)Net deferred tax liabilities(46)(65)(41)$782 $516 $631 Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations, as well as revenue and cash flow projections associated with future technologies, none of which is deductible for tax purposes.We allocated a portion of the purchase price to the specific intangible asset categories as follows:Amount Assigned(in millions)Weighted Average Amortization Period(in years)Risk-Adjusted Discount Rates used in Purchase Price AllocationBolt Medical:Amortizable intangible assets:Technology-related$142 1215%Indefinite-lived intangible assets:In-process research and development (IPR&D)$376 N/A15%$518 SoniVie:Indefinite-lived intangible assets: